What you need to know:
– PathAI, a leader in the field of AI-powered pathology, announces the launch of the Pathology Universal Transformer (PLUTO), a foundational model specifically designed for the complexity of pathology, and connects biopharmaceutical companies with pathology laboratory that is committed to transforming the development of AI tools for the lab.
– In the field of machine learning, fundamental models (FMs) play an important role. These models are trained on large amounts of unlabeled data using a technique called self-supervised learning. This process allows you to derive important information from your data, forming a strong foundation for tackling specific tasks in a variety of situations.
PLUTO Benefits: Efficiency and Performance
Utilizing a high-quality FM like PLUTO can provide significant benefits. Adapting PLUTO to specific tasks reduces development time and costs compared to building custom tools from scratch. For example, one adaptation can be used for tasks such as segmentation of cells and nuclei on microscopic immunohistochemistry (IHC) slides, or histological subtyping on whole slide his H&E slides.
Developing effective FM in pathology is particularly challenging because it involves a huge range of tasks, from cell analysis to whole slide image (WSI) evaluation. PLUTO addresses this complexity by being specifically designed to meet the diverse needs of pathology.
Building a better AI foundation
PathAI trained PLUTO on a large dataset of unlabeled image patches, including:
- Hundreds of millions of image patches
- Approximately 160,000 WSIs
- Over 30 disease areas
- Numerous signs, dirt, scanner types, magnification
- Data from over 50 sources
To ensure that PLUTO learns high-quality representations from this data, PathAI researchers implemented a customized, self-supervised training process. This process leverages a multiscale flexible deep vision transformer architecture with innovative training objectives.
PLUTO's superior performance
Rigorous evaluations have confirmed PLUTO's capabilities. When adapted to a variety of pathology tasks, PLUTO outperforms existing state-of-the-art models in areas such as whole-slide analysis, cellular tasks, and intracellular tasks.
Additionally, PLUTO supports the development of AI-powered pathology tools at various scales and resolutions. It is more compact than previous models, which significantly reduces training and inference costs. This efficiency enables highly scalable data generation and product development.
The future of pathology with AI
PLUTO and its adaptations are poised to power PathAI's industry-leading suite of next-generation AI products for biopharmaceutical companies and diagnostic pathology laboratories. PLUTO's capabilities do more than simply enhance existing products. Its embedding allows you to:
- Predict the fundamental molecular changes that drive cancer and disease phenotypes, including those that were previously undetectable with AI.
- Discovery of new biomarkers and therapeutic targets.
“PLUTO is meticulously designed to fuel research efforts for better diagnostic and prognostic tools across multiple disease areas. This technology will enable users to compress their pathology workflows using an exceptionally diverse, multi-resolution foundation model at significantly greater speed and a much broader scale than before,” said Harsha Pokalla, Head of Machine Learning at PathAI. “Our aim is to deploy this single, robust model to address a diverse range of applications and use cases within pathology and to continue developing new high performance AI tools that serve our mission to improve patient outcomes.”
